Drug intelligence / Profile preview

MAX-40391

Development stage: Unknown
Lead developer: Guangzhou Zaiji Medical Technology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MAX-40391 is a radiopharmaceutical candidate being developed by Maxinovel for the treatment of solid tumors. It is designed to target Programmed cell death 1 ligand 1 (PD-L1), a protein frequently overexpressed in various cancers to inhibit immune responses. By binding to PD-L1, MAX-40391 delivers targeted radiation directly to the tumor microenvironment, aiming to induce localized cell death while potentially enhancing the overall anti-tumor immune response. The drug is currently in early-stage development, positioned between the preclinical and Phase 1 clinical stages.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on MAX-40391.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAX-40391.

Explore the full profile